AstraZeneca PLC AstraZeneca $360m Irish manufacturing investment (4292M)
21 September 2021 - 4:00PM
UK Regulatory
TIDMAZN
RNS Number : 4292M
AstraZeneca PLC
21 September 2021
21 September 2021 07:00 BST
AstraZeneca to invest $360m in advanced manufacturing facility
in Ireland
Investment will transform development and commercialisation of
new medicines
AstraZeneca is planning on establishing a next-generation active
pharmaceutical ingredient (API) manufacturing facility for small
molecules near Dublin, Ireland to ensure the Company's global
supply network is fit for future growth.
The new plant will allow for late-stage development and early
commercial supply, adopting state of the art process technology and
digital innovation that is designed to meet the needs of the
Company's new medicines pipeline with speed and agility.
The $360m planned investment at the Alexion Campus in College
Park, Dublin, is expected to create about 100 highly skilled direct
jobs, including scientists and engineers, and further indirect
jobs. The project, which will provide an important boost to the
local economy and to the country's life-sciences sector, was
developed with the support and collaboration of Ireland's
investment agency, IDA Ireland .
Mich e ál Martin, Taoiseach, said: "I warmly welcome today's
announcement from AstraZeneca that it is to establish its first
ever manufacturing facility in Ireland. This $360 million
investment represents a significant commitment to Ireland and will
see 100 jobs being created. In choosing Ireland as the location for
its new next-generation active pharmaceutical ingredient
manufacturing facility, AstraZeneca joins the very strong and
successful network of global life sciences companies we have in
Ireland. I wish them every success with their operations here."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "This
is a tremendously proud moment for us all at AstraZeneca and I am
delighted that we are bringing this very significant investment to
Dublin which, with the support of the IDA, will create highly
skilled jobs, nurture the country's dynamic life sciences sector
and allow for the development of high value-added medicines."
Pam Cheng, Executive Vice President, Global Operations and IT,
said: "The future manufacturing of APIs for our medicines includes
compounds with highly complex synthesis, requiring next generation
technologies and capabilities that can respond quickly and nimbly
to rapidly-changing clinical and commercial needs. This significant
investment will ensure the AstraZeneca supply network is fit for
the future."
The investment programme is expected to significantly reduce
commercialisation lead times, costs and introduce more sustainable
manufacturing processes, contributing to the Company's Ambition
Zero Carbon programme. The industry-leading, future proof design of
the plant will permit the addition of capability to manufacture a
wide range of medicines, including new modalities such as antibody
drug conjugates and oligonucleotides.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @ AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team,
please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSEDSIFEFSEEU
(END) Dow Jones Newswires
September 21, 2021 02:00 ET (06:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024